Loading stock data…
$10.71-0.21 (-1.92%)
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Telix Pharmaceuticals Limited in the Healthcare sector is trading at $10.71 with a market capitalization of $3.6B. Wall Street consensus targets $20.60 (5 analysts), implying a +92.4% move over the next 12 months. The stock is currently 18% below its 52-week high of $13.11, remaining 9.6% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therape...